FDA's Dermatologic Drugs Advisory Committee
Executive Summary
Panel will review Roche's Soriatane (acitretin) capsules for the treatment of severe psoriasis on the morning of Feb. 16. Roche filed the NDA (19-821) for acitretin in February 1988. The meeting will start at 8 a.m. at FDA's Parklawn Building